Form 4: AN2 Therapeutics Chief Legal Officer Reports Stock and Option Awards

Joshua M. Eizen, Chief Legal Officer of AN2 Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• On March 15, 2024, Joshua M. Eizen, Chief Legal Officer of AN2 Therapeutics, reported transactions involving the company's securities.
• Eizen acquired 30,000 shares of common stock as restricted stock units and options to purchase 60,000 shares.
• Following these transactions, Eizen directly owns 32,447 shares of AN2 Therapeutics common stock and options to purchase 60,000 shares.
• The restricted stock units vest quarterly over four years from January 1, 2024, and the stock options vest monthly over four years from the same date, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine stock and option awards to an executive. It doesn't inherently indicate positive or negative prospects for the company.

Positives

• The acquisition of restricted stock units and stock options suggests confidence in the company's future performance from the executive.

Future Outlook

The vesting schedules for the restricted stock units and stock options are contingent upon the Reporting Person's continuous service, incentivizing long-term commitment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders by slightly diluting equity over time as the options vest and are exercised.

Key Dates